Srinagar Magazine

Rich Insights into the Medulloblastoma Pipeline and Clinical Trial Analysis Featuring 15+ Companies and Therapies

 Breaking News
  • No posts were found

Rich Insights into the Medulloblastoma Pipeline and Clinical Trial Analysis Featuring 15+ Companies and Therapies

February 28
23:04 2023
Rich Insights into the Medulloblastoma Pipeline and Clinical Trial Analysis Featuring 15+ Companies and Therapies

DelveInsight’s, “Medulloblastoma Pipeline Insight, 2023,” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in the Medulloblastoma pipeline landscape. It covers the Medulloblastoma pipeline drug profiles, including Medulloblastoma clinical trials and nonclinical stage products. It also covers the Medulloblastoma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

For Medulloblastoma Emerging drugs, the Medulloblastoma pipeline analysis report provides a 360° view of the therapeutics landscape by development point, product type, route of administration, molecule type, and MOA. The Medulloblastoma pipeline research covers business opportunities, challenges, future partnerships, strong competitors, and growth strategies.

 

In the Medulloblastoma Pipeline Report, a detailed description of the drug is given which includes the mechanism of action of the drug, Medulloblastoma clinical trials studies, Medulloblastoma NDA approvals (if any), and product development activities comprising the technology, Medulloblastoma collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.

 

Key takeaways from the Medulloblastoma Pipeline Report

 

  • Over 15+ Medulloblastoma companies are evaluating 15+ Medulloblastoma pipeline therapies in various stages of development, and their anticipated acceptance in the Medulloblastoma market would significantly increase market revenue.

 

  • The leading Medulloblastoma Companies includes Bayer, Novartis, Celgene, Y-mAbs Therapeutics, Apices Soluciones S.L., Bristol-Myers Squibb, Oncurious NV, Eli Lilly and Company, Valent technologies, Guangdong Zhongsheng Pharmaceutical, Chimerix, Kintara Therapeutics, Curtana Pharmaceuticals, VBI Vaccines, Nurix, Oncoheroes Biosciences, Midatech, and others.

 

  • Promising Medulloblastoma Pipeline Therapies includes LDE225, TMZ, Nifurtimox, Cyclophosphamide, Topotecan, TPI 287, Irinotecan, and others.

 

  • The Medulloblastoma companies and academics are working to assess challenges and seek opportunities that could influence Medulloblastoma R&D. The Medulloblastoma pipeline therapies under development are focused on novel approaches to treat/improve Medulloblastoma.

 

To explore more information on the latest breakthroughs in the Medulloblastoma Pipeline treatment landscape of the report, click here @ Medulloblastoma Pipeline Outlook

 

Medulloblastoma Overview

Medulloblastoma is a brain tumor of the cerebellum. The cerebellum controls balance and coordinated movements. The cerebellum is found near the brainstem in a region called the posterior fossa at the back of the brain. This fast-growing tumor can spread to other areas of the brain and spinal cord through cerebrospinal fluid (CSF). Symptoms of medulloblastoma depend on several things, including the tumor’s size and location, the child’s age, and stage of development. Symptoms may include: Headaches, Nausea and vomiting, Feeling tired or having changes in activity level, Clumsiness or loss of balance, Dizziness, Problems with handwriting, and Change in vision.

 

Recent Developmental Activities in the Medulloblastoma Treatment Landscape

 

  • Omburtamab-Lu-177 is a theranostic humanized monoclonal antibody 8H9, conjugated to 177 lutetium. The drug is in Phase I/II clinical development for the treatment of Medulloblastoma.

 

  • Silmitasertib (CX-4945), an oral small molecule inhibitor of casein kinase 2 (CK2). It caused cell-cycle arrest and selectively induced apoptosis in cancer cells relative to normal cells.

  

For further information, refer to the detailed Medulloblastoma Unmet Needs, Medulloblastoma Market Drivers, and Medulloblastoma Market Barriers, click here for Medulloblastoma Ongoing Clinical Trial Analysis

 

Medulloblastoma Emerging Drugs Profile

 

  • 177Lu-omburtamab-DTPA: Y-mAbs Therapeutics

Omburtamab-Lu-177 is a theranostic humanized monoclonal antibody 8H9, conjugated to 177 lutetium. The drug is in Phase I/II clinical development for the treatment of medulloblastoma. 177Lu-omburtamab-DTPA embodies the Company’s naked omburtamab antibody radiolabeled with lutetium-177, using DTPA to chelate the lutetium radioisotope to the antibody. Omburtamab antibody was developed by researchers at Memorial Sloan Kettering (“MSK”), which is exclusively licensed by MSK to Y-mAbs. As a result of this licensing arrangement, MSK has institutional financial interests in the compound and in Y-mAbs. The Committee for Orphan Medicinal Products (“COMP”) of the European Medicines Agency (“EMA”) has recommended the granting of orphan medicinal product designation (“OMPD”) in the European Union (“EU”) for 177Lu-omburtamab-DTPA for the treatment of medulloblastoma.

 

  • Silmitasertib (CX-4945): Senhwa Biosciences

Silmitasertib (CX-4945), an oral small molecule inhibitor of casein kinase 2 (CK2). It caused cell-cycle arrest and selectively induced apoptosis in cancer cells relative to normal cells. The drug is in Phase I/II clinical development for the treatment of Medulloblastoma. Silmitasertib is a first-in-class small molecule drug that targets Casein Kinase 2 (CK2), a protein involved in the DNA repair mechanism of cancer cells.

 

Medulloblastoma Pipeline Therapeutics Assessment

There are approx. 15+ key companies which are developing the therapies for Medulloblastoma. The companies which have their Medulloblastoma drug candidates in the most advanced stage, i.e. Phase II include, Y-mAbs Therapeutics.

 

Request a sample and discover the recent advances in Medulloblastoma Ongoing Clinical Trial Analysis and Medications, click here @ Medulloblastoma Treatment Landscape

 

Scope of the Medulloblastoma Pipeline Report

 

  • Coverage- Global

 

  • Medulloblastoma Companies- Bayer, Novartis, Celgene, Y-mAbs Therapeutics, Apices Soluciones S.L., Bristol-Myers Squibb, Oncurious NV, Eli Lilly and Company, Valent technologies, Guangdong Zhongsheng Pharmaceutical, Chimerix, Kintara Therapeutics, Curtana Pharmaceuticals, VBI Vaccines, Nurix, Oncoheroes Biosciences, Midatech, and others.

 

  • Medulloblastoma Pipeline Therapies– LDE225, TMZ, Nifurtimox, Cyclophosphamide, Topotecan, TPI 287, Irinotecan, and others.

 

  • Medulloblastoma Pipeline Segmentation: Product Type, Molecule Type, Route of Administration, Mechanism of Action

 

Dive deep into rich insights for drugs for Medulloblastoma Market Drivers and Medulloblastoma Market Barriers, click here @ Medulloblastoma Unmet Needs and Analyst Views

 

Table of Content 

  1. Introduction
  2. Executive Summary
  3. Medulloblastoma: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Mid Stage Products (Phase II)
  7. Drug Name: Company Name
  8. Drug profiles in the detailed report…..
  9. Early Stage Products (Phase I/II)
  10. 177Lu-omburtamab-DTPA: Y-mAbs Therapeutics
  11. Drug profiles in the detailed report…..
  12. Preclinical stage products
  13. CT 179: Curtana Pharmaceuticals
  14. Drug profiles in the detailed report…..
  15. Inactive Products
  16. Medulloblastoma Key Companies
  17. Medulloblastoma Key Products
  18. Medulloblastoma- Unmet Needs
  19. Medulloblastoma- Market Drivers and Barriers
  20. Medulloblastoma- Future Perspectives and Conclusion
  21. Medulloblastoma Analyst Views
  22. Medulloblastoma Key Companies
  23. Appendix

 

Got Queries? Find out the related information on Medulloblastoma Mergers and acquisitions, Medulloblastoma Licensing Activities @ Medulloblastoma Emerging Drugs, and Recent Trends 

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services

Related Articles